BTIG raised the firm’s price target on Boston Scientific (BSX) to $127 from $124 and keeps a Buy rating on the shares following the Q2 beat. The company can continue to outperform “sky-high expectations” through new products and clinical data, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $120 from $115 at BofA
- Morning Movers: Fiserv sinks following second quarter results
- Boston Scientific raises FY25 EPS view to $2.95-$2.99 from $2.87-$2.94
- Boston Scientific reports Q2 adjusted EPS 75c, consensus 73c
- Boston Scientific sees Q3 adjusted EPS 70c-72c, consensus 70c